Page 57 - Noble-Virtual-Healthcare-2024

ZYUS Life Sciences Corporation

SELECTED FINANCIAL ITEMS ZYUS

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue 0.06 0.06 0.06 0.07 0.24
Gross Profit (0.02) 0.04 0.03 0.01 0.06
Gross Margin -41% 64% 57% 15% 24%
EBIT (2.43) (2.21) (3.80) (2.91) (11.35)
EBIT Margin -4385% -3841% -6539% -3974% -4646%
Net Income to Common Shareholders (4.43) (3.46) (6.97) (3.10) (17.96)
Net Margin -7992% -6001% -11990% -4235% -7349%

Balance Sheet Key Items
Total Assets 47.81 47.63 60.79 53.10 53.10
Cash & Short Term Investments 0.21 0.92 16.51 7.32 7.32
% of Assets 0% 2% 27% 14% 14%
Current Assets -Total 4.63 5.11 18.31 11.52 11.52
% of Assets 10% 11% 30% 22% 22%
Total Liabilities 59.97 64.35 29.53 25.10 25.10
% of Assets 125% 135% 49% 47% 47%
Current Liabilities - Total 14.27 15.18 17.87 13.75 13.75
% of Assets 30% 32% 29% 26% 26%
Long Term Debt 22.76 25.00 0.81 0.52 0.52
% of Assets 48% 52% 1% 1% 1%
Total Equity 3.50 0.07 38.49 34.55 34.55
% of Assets 7% 0% 63% 65% 65%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.35) (1.21) 1.06 (11.06) (12.56)
Net Cash Flow - Investing (0.22) (0.03) (1.34) 4.91 3.32
Net Cash Flow - Financing 1.61 1.77 12.05 (0.65) 14.78

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference